Covis Pharma Sarl has acquired the U.S. rights to five pharmaceutical products from Sanofi-Aventis U.S. LLC.
The products, Nilandron, Plaquenil, Rilutek, Uroxatral and Kayexalate, had $114.6 million in sales for 2012. Sanofi will retain the rights to the assets outside of the U.S. Terms of the deal were not disclosed.
Nilandron is a medication used to treat prostate cancer; Planquenil is used to treat malaria or auto immune diseases; Rilutek is used to treat Lou Gehrig’s disease; Uroxatral is used to treat prostate enlargement; and Kayexalate is used to treat patients with abnormal high blood potassium levels.
Covis, headquartered in Zug, Switzerland, is a specialty pharmaceutical company.